A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

November 7, 2017

Primary Completion Date

May 17, 2019

Study Completion Date

May 17, 2019

Conditions
Migraine
Interventions
DRUG

M207 Microneedle System

M207 Microneedle System 3.8 mg

Trial Locations (31)

14609

Rochester Clinical Research, Rochester

19107

Thomas Jefferson University, Philadelphia

27262

Peters Medical Research, High Point

27607

North Carolina Clinical Research, Raleigh

27609

Raleigh Medical Group PMG Research, Raleigh

29464

Coastal Carolina Research Center, Mt. Pleasant

29621

Primary Care Associates/Radiant Research, Anderson

33016

Harmony Medical Research Institute, Hialeah

35216

Achieve Clinical Research, Birmingham

48104

Michigan Headache and Neurological Institute, Ann Arbor

55402

Clinical Research Institute, Minneapolis

55441

Clinical Research Institute, Plymouth

58103

Lillestol Research, Fargo

65810

Clinvest Research, Springfield

70124

DelRicht Research, New Orleans

75390

University of Texas Southwestern Medical Center - Neurology Clinic, Dallas

78130

Central Texas Health Research, New Braunfels

78731

FutureSearch Trials of Neurology, Austin

80230

Colorado Allergy Asthma Centers, Denver

83642

Advanced Clinical Research, Meridian

85018

Elite Clinical Studies, Phoenix

87102

Albuquerque Clinical Trials, Albuquerque

90017

Downtown L.A. Research Center, Los Angeles

90404

California Medical Clinic for Headache, Santa Monica

91786

Empire Clinical Research, Upland

94304

Stanford University Medical Center, Palo Alto

95117

Allergy Asthma Associates of Santa Clara Valley Research Center, San Jose

02131

Boston Clinical Trials, Boston

02472

MedVadis Research Corporation, Watertown

63303-3041

StudyMetrix Research LLC, City of Saint Peters

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Zosano Pharma Corporation

INDUSTRY

NCT03282227 - A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine | Biotech Hunter | Biotech Hunter